FDA Alerts

FDA Approves Biologic for Adolescents with Eczema
The FDA approved dupiliumab for the treatment of moderate to severe atopic dermatitis in adolescents.
FDA Approves New Biosimilar
The FDA has approved a new biosimilar for patients with various autoimmune diseases, including psoriasis and psoriatic arthritis.​​​​​​​
FDA Approves New Therapy for Advanced SCC ​​​​​​​ 
The FDA approved the first treatment specifically for patients with advanced cutaneous squamous cell carcinoma.
FDA Approves New Topical for Acne
The FDA has approved a new topical, once-daily lotion for the treatment of acne vulgaris in patients aged 9 years and older.​​​​​​​
Combination Therapy Approved by FDA for Melanoma
The FDA has approved a combination therapy to treat unresectable or metastatic melanoma with BRAF mutations.
FDA Approves Inclusion of New Evidence for Secukinumab
The FDA has approved the inclusion of new evidence to the prescribing label for secukinumab for the treatment of psoriatic arthritis.
FDA Expands Psoriasis Drug Indication
The FDA has approved expanding the indication for certolizumab pegol (Cimzia) to include adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
FDA Approves Dermal Filler for Hand Treatment
The FDA has approved a new dermal filler for the correction of age-related volume loss in the back of the hand for adult patients.
FDA Approves Combination Therapy for Melanoma
The US Food and Drug Administration has approved a combination therapy for patients with melanoma with BRAF V600E or V600K melanoma mutations. For administration and adverse reactions, read more.
FDA Approves New Plaque Psoriasis Treatment
The FDA approved a new therapy for the treatment plaque psoriasis among adult patients. For administration and adverse effects, read more.
Back to Top